A Confirmatory Study of MP-513 for Treatment of Type 2 Diabetes in Randomized, Double-Blind, Parallel Assignment, Placebo-Controlled Manner
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 02 Feb 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov, last updated 2 Feb 2009
- 02 Feb 2009 Actual patient numbers (324) added as reported by ClinicalTrials.gov.
- 02 Feb 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.